-
公开(公告)号：EP4051278A1
公开(公告)日：2022-09-07
申请号：EP20811814.1
申请日：2020-10-28
发明人： OZAWA, Yoichi , FUNAHASHI, Yasuhiro , KATO, Yu
IPC分类号： A61K31/47 , A61K31/53 , A61K39/395 , A61K45/06 , A61P35/00
-
2.发明公开USE OF ERIBULIN IN THE TREATMENT OF CANCER 审中-公开VERWENDUNG VON ERIBULIN BEI DER BEHANDLUNG VON KREBS
公开(公告)号：EP3148526A1
公开(公告)日：2017-04-05
申请号：EP15799560.6
申请日：2015-05-27
发明人： LITTLEFIELD, Bruce, A. , ASANO, Makoto , MATSUI, Junji , OLIVO, Martin , OZAWA, Yoichi , YU, Yanke
IPC分类号： A61K31/35 , A61K31/357 , C12Q1/68
CPC分类号： A61K31/357 , A61K9/0019 , A61K31/282 , A61K31/337 , A61K31/427 , A61K31/555 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.
摘要翻译： 本发明的特征在于在第二种药物之前通过施用艾美林或其药学上可接受的盐（例如，甲磺酸艾美林）来治疗有需要的患者的癌症的方法和试剂盒。
-
3.发明公开NOVEL USE OF SULFONAMIDE COMPOUND IN COMBINATION WITH ANGIOGENESIS INHIBITOR 审中-公开Sulfonamid-Verbindung in Kombination mit Bevacizumab
公开(公告)号：EP1862179A1
公开(公告)日：2007-12-05
申请号：EP06728638.5
申请日：2006-02-28
发明人： SEMBA, Taro, Tsukuba Research Lab., Eisai Co. Ltd. , HATA, Naoko , OZAWA, Yoichi , OWA, Takashi
IPC分类号： A61K39/395 , A61K31/18 , A61K31/404 , A61K31/381 , A61K31/498 , A61K31/64 , A61P9/00 , A61P35/00 , C07D209/30 , C07D209/42 , C07D241/44 , C07D333/34
CPC分类号： A61K45/06 , A61K31/18 , A61K31/381 , A61K31/404 , A61K31/498 , A61K31/64 , A61K39/39558 , C07D209/30 , C07D209/42 , C07D241/44 , C07D307/79 , C07D333/34 , C07K16/22 , C07K2317/24 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer and/or a method for inhibiting angiogenesis, comprising a sulfonamide compound in combination with Bevacizumab.
摘要翻译： 本发明涉及药物组合物，试剂盒和治疗癌症的方法和/或抑制血管发生的方法，其包含与贝伐单抗组合的磺酰胺化合物。
-
公开(公告)号：EP3581183A1
公开(公告)日：2019-12-18
申请号：EP18751614.1
申请日：2018-02-06
摘要： Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
-
公开(公告)号：EP3311841A1
公开(公告)日：2018-04-25
申请号：EP16811667.1
申请日：2016-06-15
发明人： ODAGAMI, Takenao , KOUJI, Hiroyuki , OZAWA, Yoichi , HORI, Yusaku
IPC分类号： A61K45/06 , A61K31/519 , A61K31/53 , A61K39/395 , A61P35/00 , A61P43/00
CPC分类号： A61K31/675 , A61K31/519 , A61K31/53 , A61K39/395 , A61K39/3955 , A61K45/06 , A61P35/00
摘要： The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.
摘要翻译： 本发明的目的在于提供具有优异治疗效果的癌症治疗药物。 联合使用CBP /连环蛋白抑制剂和免疫检查点抑制剂的癌症治疗不仅增加对癌症的治疗效果，而且当单独使用免疫检查点抑制剂时，能够有效治疗表现出低敏感性的癌症患者。
-
6.发明授权MEDICINAL COMPOSITIONS COMPRISING N-(3-CHLORO-1H-INDOL-7-YL)-4-SULFAMOYLBENZENESULFONAMIDE AND FURTHER CYTOSTATICS 有权医学COMPOSITIONS CONTAINING N-（3-氯-1H-吲哚-7-基）-4- SULFAMOYLBENZENSULFONAMID AND MORE细胞抑制剂
公开(公告)号：EP1622624B1
公开(公告)日：2007-12-26
申请号：EP04730660.0
申请日：2004-04-30
发明人： OZAWA, Yoichi
IPC分类号： A61K31/635 , A61K31/555 , A61K31/505 , A61K31/7072 , A61P35/00
CPC分类号： A61K45/06
摘要： The present invention provides a medicinal composition having an excellent antitumor activity. That is, it provides a medicinal composition comprising N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide or a salt thereof, combined with at least one substance selected from (1) carboplatin; (2) oxaliplatin; (3) capecitabine; and (4) a salt of the above-mentioned (1) to (3).
-
7.发明公开NOVEL CONCOMITANT USE OF SULFONAMIDE COMPOUND WITH ANTI-CANCER AGENT 审中-公开GLEICHZEITIGE VERWENDUNG EINER SULFONAMID-VERBINDUNG IN EINES MITTELS GEGEN KREBS
公开(公告)号：EP1859797A1
公开(公告)日：2007-11-28
申请号：EP06715262.9
申请日：2006-02-28
发明人： OWA, Takashi , OZAWA, Yoichi , SEMBA, Taro , HATA, Naoko
IPC分类号： A61K31/404 , A61K31/18 , A61K31/343 , A61K31/381 , A61K31/4741 , A61K31/498 , A61K31/7068 , A61K33/24 , A61K45/00 , A61P9/00 , A61P35/00
CPC分类号： A61K31/498 , A61K31/18 , A61K31/343 , A61K31/381 , A61K31/404 , A61K31/4741 , A61K31/7068 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition, a kit, a method of treating cancer and/or a method of inhibiting angiogenesis comprising a sulfonamide compound in combination with a platinum complex, a DNA-topoisomerase I inhibitor, an antimetabolite, a microtubule inhibitor or an antibiotic.
摘要翻译： 本发明涉及药物组合物，试剂盒，治疗癌症的方法和/或抑制血管发生的方法，其包括与铂络合物，DNA拓扑异构酶I抑制剂，抗代谢物，微管抑制剂或抗微管蛋白酶抑制剂组合的磺酰胺化合物 一种抗生素。
-
公开(公告)号：EP3284752A1
公开(公告)日：2018-02-21
申请号：EP16780097.8
申请日：2016-04-14
发明人： SAKAMOTO, Yoshimasa , ADACHI, Yusuke , MATSUI, Junji , KATO, Yu , OZAWA, Yoichi , ABE, Takanori , ITO, Ken , NAKAZAWA, Yuya , TACHINO, Sho , SUZUKI, Katsuhisa , AGARWALA, Kishan , HOSHINO, Kana , KATAYAMA, Masahiko
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , C12N15/09
CPC分类号： C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61P35/00 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
摘要： The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
摘要翻译： 本发明提供可具有针对人Notch4的中和活性的抗人Notch4抗体或Notch4结合片段，以及包含其作为活性成分的药物组合物。 本发明人获得了对人Notch4具有高中和活性和结合亲和力的小鼠抗人Notch4抗体，并确定了所述小鼠抗人Notch4抗体的互补决定区（CDR）序列。 这使得能够产生包含重链和轻链的可变区以及所述小鼠抗人Notch4抗体的CDR序列的人源化抗体。
-
公开(公告)号：EP4209216A1
公开(公告)日：2023-07-12
申请号：EP21886203.5
申请日：2021-10-26
发明人： HOSHI, Taisuke , KATO, Yu , OZAWA, Yoichi , KAWANO, Satoshi , KODAMA, Kotaro , MIYANO, Saori
IPC分类号： A61K31/4545 , A61K39/395 , A61K45/00 , A61P15/00 , A61P35/00 , A61P35/04 , A61P43/00
摘要： Provided is a pharmaceutical composition for treating a tumor, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or its pharmaceutically acceptable salt, which is to be administered in combination with a PD-1 antagonist.
-
公开(公告)号：EP1433479B8
公开(公告)日：2008-01-23
申请号：EP02767898.6
申请日：2002-09-05
发明人： OWA, Takashi , OZAWA, Yoichi , HIDA, Takayuki , MIYAMOTO, Norimasa , NAGASU, Takeshi , OKAUCHI, Tatsuo , YOSHINO, Hiroshi , HATA, Naoko , YOSHIMATSU, Kentaro , KOYANAGI, Nozomu , KITO, Kyosuke
IPC分类号： A61K31/404 , A61K31/4178 , A61K31/427 , A61K31/4439 , A61K45/00 , A61P1/14
CPC分类号： C07D401/12 , A23L33/10 , A61K31/4035 , C07D209/08 , C07D209/12 , C07D209/30 , C07D209/34 , C07D209/42 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D471/04
摘要： Appetite-stimulating agents containing as the active ingredient sulfonamide or sulfonic ester derivatives represented by the general formula (I), pharmacologically acceptable salts thereof, or hydrates of both: (I) wherein A is an optionally substituted mono- or bi-cyclic aromatic ring; B is an optionally substituted six-membered unsaturated hydrocarbon ring or an unsaturated six-membered heterocycle containing one nitrogen atom; C is an optionally substituted five-membered heterocycle containing one or two nitrogen atoms; W is a single bond or -CH=CH-; X is -N(R1)- or oxygen; Y is carbon or nitrogen; Z is -N(R2)- or nitrogen; and R1 and R2 are each independently hydrogen or lower alkyl.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.018 秒)
